Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BouNDless ND0612 vs oral IR levodopa/carbidopa in Parkinson's disease with motor fluctuations
2024-511940-20-00Phase 3Authorised
- Sponsor
- NeuroDerm Ltd.
- Start
- May 2024
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Planned start May 2024; status: authorised.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-511940-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511940-20-00.